Thus, the present study aimed to investigate the response of generic TKIs in patients with newly diagnosed CML-CP and to analyze BCR-ABL TK domain mutations in CML-CP patients with TKI failure. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.